Page last updated: 2024-12-07
7-aminocholesterol
Description
7-aminocholesterol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
7-aminocholesterol : A 3beta-sterol that is cholesterol substituted at position 7 by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 133019 |
| CHEBI ID | 77845 |
| SCHEMBL ID | 1070587 |
| MeSH ID | M0234873 |
Synonyms (12)
| Synonym |
|---|
| 7-aminocholest-5-en-3-ol (3beta)- |
| 156856-03-0 |
| cholest-5-en-3-ol, 7-amino-, (3beta)- |
| (3beta)-7-aminocholest-5-en-3-ol |
| 7-aminocholesterol |
| (3s,8s,9s,10r,13r,14s,17r)-7-amino-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol |
| SCHEMBL1070587 |
| CHEBI:77845 |
| 7-aminocholest-5-en-3beta-ol |
| Q27147457 |
| 7-aminocholest-5-en-3-ol |
| DTXSID40935544 |
Roles (1)
| Role | Description |
|---|
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| cholestanoid | Any steroid based on a cholestane skeleton and its derivatives. |
| 3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
| primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
| 3beta-hydroxy-Delta(5)-steroid | Any 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.60 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.39 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |